A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.
Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.
Recently updated diagnostic criteria for fibromyalgia that reduce the underdiagnosis in men had not been implemented during these studies.
With little being known about the predictors or moderators of dTMS outcome for OCD, this study sought to examine if several theoretically relevant variables may predict and moderate treatment effects including OCD symptom severity, functional impairment, co-occurring depressive symptoms, age, gender, age of OCD onset, and family history of OCD.
While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.
Exploring the risk of alcohol use disorders in patients with insomnia.